Progressive Supranuclear Palsy (Psp) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disorder that significantly impacts movement, thinking, speech, and vision. It is commonly referred to as an "atypical parkinsonism" because of its overlap of certain symptoms with Parkinson's Disease. PSP involves abnormal tau protein accumulation in the brain, leading to progressive neuronal loss in multiple brain regions.
PSP is an adult-onset neurological disease that impacts brain cells controlling balance, coordination, eye movement, speech, swallowing, and cognitive function. The condition is characterized by tau protein clumps (neurofibrillary tangles) that form in various brain regions, causing neuronal dysfunction and death.
The average symptom onset occurs in the early 60s, but may start as early as in the 40s. PSP is slightly more common in men than women and affects approximately 6-10 individuals per 100,000, with about 30,000 cases in the United States (likely underestimates due to misdiagnosis).
- Prevalence: 6-10 individuals per 100,000
- Cases in US: Approximately 30,000 (likely underestimated)
- Onset: Early 60s, but can begin as early as 40s
- Gender: Slightly more common in men than women
¶ Movement and Balance Issues
- Balance problems: Frequent falls, characteristically falling backwards (unlike Parkinson's patients who fall forward)
- Slowed movements: Involuntary slowness in feet, legs, torso, neck, arms, and hands
- Freezing of gait: The involuntary and temporary inability to move the legs and feet
- Postural instability: Changes to the usual alignment of the body
- Rigidity: Muscles stiffen and create resistance to movement
- Dystonia: Muscle contractions across legs, trunk, torso, arms, hands, and feet
- Apraxia: Loss of the ability to carry out intentional movements
¶ Visual and Ocular Symptoms
Ocular symptoms are hallmark features distinguishing PSP from other movement disorders:
- Eye movement apraxia: Impaired ability to move the eyes up or down — described as "unique to PSP and distinguishes it from Parkinson's and general aging"
- Square wave jerks: Jerky eye movements
- Double vision
- Blepharospasm: Involuntary eyelid closure
- Reduced blinking: 3-4 times per minute versus the normal 15-25
¶ Speech and Swallowing
- Speech changes: Irregular, explosive, or rubber band quality (spastic speech) or slurred, drunken quality (ataxic speech)
- Swallowing difficulties: Weakness and incoordination of throat muscles, increasing risk of aspiration and pneumonia
¶ Cognitive and Behavioral Changes
- Aphasia: Difficulty finding words, expressing thoughts, and understanding language
- Behavioral changes: Impulsivity, poor judgment, and lack of insight
- Apathy: Less motivation to partake in activities
- Impulsivity coupled with imbalance is the primary reason that people with PSP fall
The direct cause of PSP "is not fully understood," but the condition involves:
- tau protein clumps: Abnormal folding causes tau to stick together and become stuck inside the cell
- Neurofibrillary tangles: Areas of the brain with tau-containing cells show neuron impairment and neuronal death
- The areas most affected include the brainstem, basal ganglia, and frontal lobes
- About 95% of people with PSP carry the H1 haplotype variant on chromosome 17 (compared to about 60% of people without PSP)
- This genetic variant affects the MAPT gene encoding the tau protein
No single test exists for PSP. Diagnosis involves:
- Medical history review: Neurological symptoms, onset timing, impact on daily functioning
- Physical examination: How a person walks, speaks, moves their eyes, feet, and hands
- MRI imaging: Shows characteristic "hummingbird sign" or "penguin sign" — noticeable atrophy in the midbrain
- Additional tests: Blood tests, neuropsychological evaluation, DaTscan, PET scans
- Medication response assessment
Ten distinct PSP subtypes have been identified:
- PSP-Richardson's Syndrome: Classic form
- PSP-Parkinsonism
- PSP-Progressive Gait Freezing
- PSP-Speech/Language
- PSP-Corticobasal Syndrome
- PSP-Frontal
- PSP-Ocular Motor
- PSP-Postural Instability
- PSP-Primary Lateral Sclerosis
- PSP-Cerebellar
A multidisciplinary approach is essential:
- Movement disorder specialist
- Physical therapist (PT)
- Occupational therapist (OT)
- Speech-language pathologist (SLP)
- Clinical social worker (SW)
- Nutritionist, pharmacist, and mental health specialists
Physical therapy: Prevents falls, addresses balance and walking issues, teaches safer transfer and walking assistance
Occupational therapy: Modifies activities and hobbies, provides adaptive equipment (grab bars, weighted utensils, bed rails)
Speech-language pathology: Addresses communication techniques and swallowing safety
- Carbidopa/levodopa: Primary Parkinson's medication; benefits are unpredictable, usually modest, and wear off after only a few years
- Antidepressants: SSRIs and SNRIs may help; tricyclic antidepressants (TCAs) can impact cognitive function and should be avoided
- Coenzyme Q-10: Might show promise to help with gait and balance
- Feeding tubes (PEG tubes): Considered when swallowing difficulties prevent adequate nutrition, helping prevent weight loss and decrease aspiration risk
PSP and Corticobasal Degeneration (CBD) share significant clinical and pathological overlap:
- Both are tauopathies involving the H1 haplotype
- PSP-CBD syndrome is one of the recognized subtypes of PSP
- Both involve progressive motor dysfunction and cognitive decline
- Tau pathology in both conditions shows similar patterns of regional distribution
- Parkinson's Disease: Shares some symptoms but distinct progression pattern (falls backward vs. forward)
- Alzheimer's Disease: Both involve tau pathology but different regional patterns
- FTD: Shares behavioral and cognitive symptoms in some subtypes
- MSA: Another atypical parkinsonism with overlapping features
- Understanding tau protein propagation
- Developing biomarkers for early diagnosis
- Disease-modifying therapies targeting tau
- Clinical trials for novel therapeutics
- Genetic studies of risk factors
The following resources provide additional data on genes and proteins related to Amyotrophic Lateral Sclerosis (ALS):
The following questions are prioritized for near-term experimental and translational work. They are intended to guide hypothesis generation, preclinical design, and trial strategy.
- Which molecular forms of 4R-tau best explain clinical heterogeneity across Progressive Supranuclear Palsy (PSP) syndromes?
- How should plasma and CSF biomarker panels be standardized to differentiate PSP from Parkinson's Disease and Multiple System Atrophy (MSA) at first specialist visit?
- Which imaging signatures most reliably separate PSP-Richardson syndrome from cortical and speech-language variants in early disease?
- How can progression models combine falls, ocular motor decline, and cognitive metrics to improve trial power?
- What role do immune and metabolic pathway signatures play in high tau-seeding PSP subtypes?
- How should MAPT, APOE, and emerging loci such as NFASC influence molecular stratification strategies?
- Which brain regions should be prioritized for target-engagement readouts in anti-tau interventional studies?
- How do microglia-driven inflammatory states interact with tau seeding and network degeneration in PSP?
- Can adaptive platform trials in PSP align enrichment to biomarker-confirmed subtypes while preserving feasible enrollment?
- What endpoints best capture patient-relevant benefit beyond motor scales, including communication and executive function?
- How should natural-history cohorts be harmonized internationally to support external controls for rare tauopathy trials?
- What mechanisms determine variable survival and disability trajectories among clinically similar PSP patients?
- Prospective multimodal cohorts linking molecular biomarkers to deep phenotyping.
- Cell-type-resolved perturbation studies in disease-relevant human models.
- Adaptive platform trials with mechanism-enriched enrollment criteria.
- Prospective multicenter cohorts harmonizing plasma/CSF biomarkers with phenotype-specific progression endpoints.
- Validated biomarkers that distinguish PSP subtypes and support adaptive enrichment in early-phase clinical trials.
- Mechanistic studies linking tau-seeding heterogeneity to immune-metabolic pathway differences in patient tissue.
- Distinct 4R-tau conformer subtypes as the primary driver of clinical heterogeneity versus downstream consequence of region-specific vulnerability.
- PSP progression primarily determined by distributed network degeneration versus predominantly brainstem-initiated spread dynamics.
- Biomarker-guided molecular enrichment versus phenotype-first enrollment as the better strategy for disease-modifying trial success in PSP.
- Prospective multimodal cohorts linking molecular biomarkers to deep phenotyping.
- Cell-type-resolved perturbation studies in disease-relevant human models.
- Adaptive platform trials with mechanism-enriched enrollment criteria.
- Prospective multicenter cohorts harmonizing plasma/CSF biomarkers with phenotype-specific progression endpoints.
- Validated biomarkers that distinguish PSP subtypes and support adaptive enrichment in early-phase clinical trials.
- Mechanistic studies linking tau-seeding heterogeneity to immune-metabolic pathway differences in patient tissue.
- Distinct 4R-tau conformer subtypes as the primary driver of clinical heterogeneity versus downstream consequence of region-specific vulnerability.
- PSP progression primarily determined by distributed network degeneration versus predominantly brainstem-initiated spread dynamics.
- Biomarker-guided molecular enrichment versus phenotype-first enrollment as the better strategy for disease-modifying trial success in PSP.
- Prospective multimodal cohorts linking molecular biomarkers to deep phenotyping.
- Cell-type-resolved perturbation studies in disease-relevant human models.
- Adaptive platform trials with mechanism-enriched enrollment criteria.
- Prospective multicenter cohorts harmonizing plasma/CSF biomarkers with phenotype-specific progression endpoints.
- Validated biomarkers that distinguish PSP subtypes and support adaptive enrichment in early-phase clinical trials.
- Mechanistic studies linking tau-seeding heterogeneity to immune-metabolic pathway differences in patient tissue.
- Distinct 4R-tau/proteins/tau conformer subtypes as the primary driver of clinical heterogeneity versus downstream consequence of region-specific vulnerability.
- PSP progression primarily determined by distributed network degeneration versus predominantly brainstem-initiated spread dynamics.
- Biomarker-guided molecular enrichment versus phenotype-first enrollment as the better strategy for disease-modifying trial success in PSP.
- Prospective multimodal cohorts linking molecular biomarkers to deep phenotyping.
- Cell-type-resolved perturbation studies in disease-relevant human models.
- Adaptive platform trials with mechanism-enriched enrollment criteria.
- Prospective multicenter cohorts harmonizing plasma/CSF biomarkers with phenotype-specific progression endpoints.
- Validated biomarkers that distinguish PSP subtypes and support adaptive enrichment in early-phase clinical trials.
- Mechanistic studies linking tau-seeding heterogeneity to immune-metabolic pathway differences in patient tissue.
- Distinct 4R-tau/proteins/tau conformer subtypes as the primary driver of clinical heterogeneity versus downstream consequence of region-specific vulnerability.
- PSP progression primarily determined by distributed network degeneration versus predominantly brainstem-initiated spread dynamics.
- Biomarker-guided molecular enrichment versus phenotype-first enrollment as the better strategy for disease-modifying trial success in PSP.
- Prospective multimodal cohorts linking molecular biomarkers to deep phenotyping.
- Cell-type-resolved perturbation studies in disease-relevant human models.
- Adaptive platform trials with mechanism-enriched enrollment criteria.
- Prospective multicenter cohorts harmonizing plasma/CSF biomarkers with phenotype-specific progression endpoints.
- Validated biomarkers that distinguish PSP subtypes and support adaptive enrichment in early-phase clinical trials.
- Mechanistic studies linking tau-seeding heterogeneity to immune-metabolic pathway differences in patient tissue.
- Distinct 4R-tau/proteins/tau conformer subtypes as the primary driver of clinical heterogeneity versus downstream consequence of region-specific vulnerability.
- PSP progression primarily determined by distributed network degeneration versus predominantly brainstem-initiated spread dynamics.
- Biomarker-guided molecular enrichment versus phenotype-first enrollment as the better strategy for disease-modifying trial success in PSP.
- Prospective multimodal cohorts linking molecular biomarkers to deep phenotyping.
- Cell-type-resolved perturbation studies in disease-relevant human models.
- Adaptive platform trials with mechanism-enriched enrollment criteria.
- Prospective multicenter cohorts harmonizing plasma/CSF biomarkers with phenotype-specific progression endpoints.
- Validated biomarkers that distinguish PSP subtypes and support adaptive enrichment in early-phase clinical trials.
- Mechanistic studies linking tau-seeding heterogeneity to immune-metabolic pathway differences in patient tissue.
- Distinct 4R-tau/proteins/tau conformer subtypes as the primary driver of clinical heterogeneity versus downstream consequence of region-specific vulnerability.
- PSP progression primarily determined by distributed network degeneration versus predominantly brainstem-initiated spread dynamics.
- Biomarker-guided molecular enrichment versus phenotype-first enrollment as the better strategy for disease-modifying trial success in PSP.
The study of Progressive Supranuclear Palsy (Psp) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.